CUBICIN® Company Profile

21:00 EST 12th December 2018 | BioPortfolio

CUBICIN® (daptomycin for injection), the only once-a-day agent approved for the treatment of MRSA and MSSA in cSSSI, has been shown to be safe1 and effective2 against most Gram-positive organisms in cSSSI.
Click here to view the progression of an actual case of left-ankle cellulitis successfully treated with CUBICIN therapy.
Rapidly bactericidal in vitro,* CUBICIN is the first cyclic lipopeptide and has a mechanism of action distinct from that of any other antibiotic.
With its once-a-day dosing, 30-minute infusion time, and other conveniences, CUBICIN is an ideal agent for outpatient MRSA/MSSA cSSSI care. (Preparation and Administration instructions.)
Questions about billing and reimbursement? Check out our Billing Guide for Cubicin® online or download the pdf.


Lexington Headquarters65 Hayden Avenue
United States of America


Phone: 781-860-8660
Fax: 781-861-0566

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Cubicin [Cubist Pharmaceuticals, Inc.]

These highlights do not include all the information needed to use CUBICIN safely and effectively.  See full prescribing information for CUBICIN. CUBICIN (daptomycin for injection) for Intravenous Use...

PubMed Articles [0 Results]


Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Cubicin(R) for Complicated Post-Surgical Wound Infections

The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections

China Registration Study in Patients With Skin Infections

The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthet...

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis

multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the trea...

Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

The purpose of the study is to evaluate the overall burden to the participant (economic, quality of life, patients satisfaction and freedom from side effects) when treating Gram positive i...

Companies [1 Associated Companies listed on BioPortfolio]


CUBICIN® (daptomycin for injection), the only once-a-day agent approved for the treatment of MRSA and MSSA in cSSSI, has been shown to be safe1 and effective2 against most Gram-positive organisms in ...

More Information about "CUBICIN®" on BioPortfolio

We have published hundreds of CUBICIN® news stories on BioPortfolio along with dozens of CUBICIN® Clinical Trials and PubMed Articles about CUBICIN® for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CUBICIN® Companies in our database. You can also find out about relevant CUBICIN® Drugs and Medications on this site too.

Quick Search


Relevant Topics

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Corporate Database Quicklinks

Searches Linking to this Company Record